XML 91 R80.htm IDEA: XBRL DOCUMENT
v3.25.3

COMMITMENTS AND CONTINGENCIES - Narrative (Details) $ in Thousands | 3 Months Ended | 9 Months Ended | 12 Months Ended |
--- | --- | --- | --- | ---
Jun. 30, 2025 USD ($) | Mar. 31, 2025 USD ($) | Jun. 30, 2024 USD ($) | Sep. 30, 2025 USD ($) liability | Sep. 30, 2024 USD ($) | Dec. 31, 2022 USD ($) payment | Dec. 31, 2019 USD ($)
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Payment for contingent consideration |  |  |  | $ 16,451 | $ 11,923 |  |
Arkis |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to) |  |  |  |  |  |  | $ 25,500
Contingent consideration |  |  |  |  |  |  | 13,100
Arkis | Development Milestones |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to) |  |  |  |  |  |  | 10,000
Payment for contingent consideration |  | $ 5,000 |  |  |  |  |
Arkis | Commercial Sales Milestones |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to) |  |  |  |  |  |  | $ 15,500
Derma Sciences |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Number of liabilities | liability |  |  |  | 1 |  |  |
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to) |  |  |  | $ 3,000 |  |  |
Derma Sciences | BioD Earnout Payments and Medihoney Earnout Payments |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Payment for contingent consideration |  |  |  | $ 33,300 |  |  |
ACell, Inc. |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Number of liabilities | liability |  |  |  | 1 |  |  |
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to) |  |  |  | $ 23,900 |  |  |
ACell, Inc. | Revenue-Based Performance Milestones In 2023 |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to) |  |  |  | $ 100,000 |  |  |
Surgical Innovation Associates, Inc. |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to) |  |  |  |  |  | $ 90,000 |
Business acquisition, number of payments | payment |  |  |  |  |  | 2 |
Surgical Innovation Associates, Inc. | Revenue Based Performance Milestones |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to) |  |  |  |  |  | $ 32,600 |
Payment for contingent consideration | $ 18,100 |  | $ 12,400 |  |  |  |
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to) |  |  |  |  |  | 50,000 |
Surgical Innovation Associates, Inc. | FDA Approval Of Premarket Approval |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to) |  |  |  |  |  | 25,000 |
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to) |  |  |  |  |  | $ 40,000 |

X
- Definition Business Acquisition, Number Of Contingent Liabilities + References No definition available. + Details
Name: | iart_BusinessAcquisitionNumberOfContingentLiabilities
Namespace Prefix: | iart_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business Combination, Contingent Consideration, Number Of Liabilities + References No definition available. + Details
Name: | iart_BusinessCombinationContingentConsiderationNumberOfLiabilities
Namespace Prefix: | iart_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Maximum amount of estimate for undiscounted range of outcomes in contingent consideration arrangement in business combination. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 43 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 43 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of preacquisition contingent liability assumed in business combination and recognized at acquisition date. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 275 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (f) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details
Name: | us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=iart_ArkisBioSciencesInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=iart_DevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=iart_CommercialSalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=iart_DermaSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=iart_BioDEarnoutPaymentsandMedihoneyEarnoutPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=iart_ACellIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=iart_RevenueBasedPerformanceMilestonesIn2023Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=iart_SurgicalInnovationAssociatesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=iart_RevenueBasedPerformanceMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=iart_FDAApprovalOfPremarketApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |